You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

293 Results
Document
Dec 2023
Document
Dec 2023
Document
Dec 2023
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    filgrastim (biosimilars) - refer to ODB Formulary for details
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
filgrastim,
IDArubicin,
fludarabine,
cytarabine,
venetoclax (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
*/
Document
Jan 2025
Document
Apr 2025
Document
Jun 2025
Document
Jun 2025
Document
Jun 2025

Pages